interaction records 54 assistance programs 55 0 personal data stored
OmniRx › Tools › Generic competition check › Pimavanserin Tartrate

Generic competition · all medicines · read 12 November 2026

Is there a generic of Pimavanserin Tartrate, and who makes it?

Pimavanserin Tartrate appears in 2 dosage-form groups in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed. 2 groups have a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming. Where both are dated, the first generic approval came between 5.6 and 7.7 years after the first brand approval. This is the Orange Book's listing, not a forecast.

Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the Orange Book data files, downloaded 12 November 2026.

Not medical advice. This page reports what the FDA's Orange Book lists, not what a pharmacy has in stock, what anything costs, or whether a generic is right for you. Ask your pharmacist or prescriber about your own medicine.
Pimavanserin Tartrate2 dosage-form groups in the Orange Book
0generic makers listed
  1. Pimavanserin Tartrate appears in 2 dosage-form groups in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed.
  2. 2 groups have a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming.
  3. Where both are dated, the first generic approval came between 5.6 and 7.7 years after the first brand approval.
  4. Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.

Capsule, Oral

Brand listed, no generic listed as marketed

Brand listed as marketed: Nuplazid. No generic is listed as marketed (2 generic products listed as discontinued).

20152020202520302035204001brand 2018data datePatent 7732615 listed to expire 3 June 2028Patent 7732615*PED listed to expire 3 December 2028Patent 7601740 listed to expire 29 April 2030Patent 7601740*PED listed to expire 29 October 2030Patent 10849891 listed to expire 27 August 2038Patent 11452721 listed to expire 27 August 2038Patent 10449185 listed to expire 27 August 2038Patent 10646480 listed to expire 27 August 2038Patent 10449185*PED listed to expire 27 February 2039Patent 10646480*PED listed to expire 27 February 2039Patent 10849891*PED listed to expire 27 February 2039Patent 11452721*PED listed to expire 27 February 2039Exclusivity M-14 to 27 April 2029Exclusivity PED to 27 October 2029
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

  • 27 April 2029Exclusivity M-14 Nuplazid
  • 27 October 2029Exclusivity PED Nuplazid
  • 3 June 2028Patent 7732615 drug substance
  • 3 December 2028Patent 7732615*PED
  • 29 April 2030Patent 7601740 drug substance
  • 29 October 2030Patent 7601740*PED
  • 27 August 2038Patent 10849891 drug product
  • 27 August 2038Patent 11452721 drug product
  • 27 August 2038Patent 10449185 drug product
  • 27 August 2038Patent 10646480 drug product

4 more patents are listed.

Tablet, Oral

Brand listed, no generic listed as marketed

Brand listed as marketed: Nuplazid. No generic is listed as marketed (1 generic product listed as discontinued).

20152020202520302035204001brand 2016data datePatent 7732615 listed to expire 3 June 2028Patent 7732615*PED listed to expire 3 December 2028Patent 7601740 listed to expire 29 April 2030Patent 7601740*PED listed to expire 29 October 2030Patent 10517860 listed to expire 23 March 2037Patent 10953000 listed to expire 23 March 2037Patent 10953000*PED listed to expire 23 September 2037Patent 10517860*PED listed to expire 23 September 2037Exclusivity M-14 to 27 April 2029Exclusivity PED to 27 October 2029
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

  • 27 April 2029Exclusivity M-14 Nuplazid
  • 27 October 2029Exclusivity PED Nuplazid
  • 3 June 2028Patent 7732615 drug substance
  • 3 December 2028Patent 7732615*PED
  • 29 April 2030Patent 7601740 drug substance
  • 29 October 2030Patent 7601740*PED
  • 23 March 2037Patent 10517860
  • 23 March 2037Patent 10953000
  • 23 September 2037Patent 10953000*PED
  • 23 September 2037Patent 10517860*PED

US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.

Where can you go from this result?

Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.